Related Experiment Video
Updated: Jun 1, 2026
10:03
Development of Leishmania Species Strains with Constitutive Expression of eGFP
Published on: April 21, 2023
Recent advances in leishmaniasis treatment.
Tatiana S Tiuman1, Adriana O Santos, Tânia Ueda-Nakamura
1Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, Av. Colombo 5790, 87020-900 Maringá, Paraná, Brazil.
Summary
This review explores treatments for Leishmania infections, including plant-derived and synthetic drugs. Novel drug delivery systems like nanoparticles offer new avenues for developing effective anti-Leishmania therapies.
Area of Science:
- Tropical medicine
- Pharmacology
- Drug discovery
Background:
- Leishmania infections cause significant global morbidity, with millions of new cutaneous and visceral leishmaniasis cases annually.
- Pentavalent antimonial compounds have been the primary treatment for over 50 years, highlighting an urgent need for alternative therapies.
- Existing treatments face challenges, necessitating exploration of novel therapeutic strategies.
Purpose of the Study:
- To review current and emerging therapeutic options for Leishmania infections.
- To highlight advancements in plant-derived and synthetic compounds as potential anti-Leishmania drugs.
- To discuss innovative drug delivery systems for improved treatment efficacy.
Main Methods:
- Comprehensive literature review of existing treatments for Leishmania.
- Analysis of research on natural products (plants) and synthetic compounds for anti-Leishmania activity.
- Evaluation of novel drug delivery systems, including nanoparticles and liposomes.
Main Results:
- Pentavalent antimonials remain a mainstay, but resistance and toxicity are concerns.
- Research is yielding promising plant extracts and synthetic compounds with anti-Leishmania potential.
- Advanced delivery systems like nanoparticles and liposomes show potential for enhanced drug efficacy and targeted delivery.
Conclusions:
- There is a critical need for novel anti-Leishmania drugs due to limitations of current treatments.
- Pharmaceutical industry engagement with modern technologies is crucial for developing effective plant-based and synthetic therapeutics.
- Innovative drug delivery strategies are essential for the future design of potent anti-Leishmania chemotherapeutics.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...